SG/CALL/EDWARDS LIFESCIENCES/60/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 20:45:39 31/05/2024 BST | ||
| 2.41 EUR | -6.23% |
|
| 1 month | +1.69% | ||
| 3 months | -4.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 2.41 | -6.23% |
| 30/05/24 | 2.57 | +2.39% |
| 29/05/24 | 2.51 | +0.40% |
| 28/05/24 | 2.5 | +1.63% |
| 27/05/24 | 2.46 | -5.02% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 08:45 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SU2L99 |
| ISIN | DE000SU2L990 |
| Date issued | 22/11/2023 |
| Strike | 60 $ |
| Maturity | 21/06/2024 (19 Days) |
| Parity | 10 : 1 |
| Emission price | 1.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.4 € |
|---|---|
| Lowest since issue | 1.24 € |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
86.89
USD
Average target price
96.55
USD
Spread / Average Target
+11.12%
- Stock Market
- Warrants
- Warrant
